Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on March 24, 2022. The filing serves to announce the Company's financial results for the year and quarter ended December 31, 2021. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of a press release containing the results for the period ended December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated March 24, 2022), as they are absent from this 8-K summary.
- Confirm the Company name is Ocuphire Pharma, Inc. (OCUP), noting the discrepancy with the metadata request for "Opus Genetics, Inc."
- Review the full press release for any operational updates or clinical trial milestones not detailed in this current report.
- Check the Company's status as an emerging growth company for potential differences in financial reporting standards.